Sign inJoin waitlistJoin the waitlist

Mark Hamblin

Associate Professor, Pulmonary, Critical Care and Sleep Medicine · University of Kansas School of Medicine

Credentials: · · · · · ·

History

University of Kansas School of Medicine
Present

Pulmonary Disease and Critical Care Medicine
2006–2009
Internal Medicine
2003–2006
University of Missouri School of Medicine
1999–2003

Research

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
JAMA · 2018 · 189 citations
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series
Neurology · 2017 · 152 citations
Diagnosis, course and management of hypersensitivity pneumonitis
Review · European Respiratory Review · 2022 · First of 3 authors · Corresponding · 95 citations

Ganesh Raghu
4 papers
Sahil Pandya
4 papers · 4 as a fellow
AB
Anne Brown
3 papers
DA
Danielle Antin-Ozerkis
3 papers
Jeffrey Golden
3 papers
Keith Meyer
3 papers
Lawrence Ho
3 papers
MH
Maureen Horton
3 papers
Scott Matson
3 papers
Toby Maher
3 papers
Camilla Graham
2 papers
Caroline Muegge
2 papers · 2 as a fellow

Clinical trials

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Principal investigator · Completed · Phase 2
Kyntra Bio
2013–2017
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
Site PI · Not yet recruiting · Phase 2
University of Alabama at Birmingham
2026–2031
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Site PI · Recruiting · Phase 2
Rein Therapeutics
2026–2027
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Site PI · Recruiting · Phase 2
Avalyn Pharma Inc.
2025–2031